Mitiperstat
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Mitiperstat
- Molecular weight
- 334.83
- Structure (SMILES)
- C[C@@H](N)c1cc(Cl)ccc1Cn1c(=S)[nH]c(=O)c2[nH]ccc21
- azd 4831
- Azd 4831
- AZD 4831 [WHO-DD]
- azd 4831 who dd
- AZD-4831
- azd4831
- AZD4831
- mitiperstat
- Mitiperstat
- Mitiperstat (AZD4831)
- mitiperstat [INN]
- MITIPERSTAT [USAN]
- mitiperstat inn
- mitiperstat usan
- CAS registry numbers
- 1933460-19-5
- ChEMBL ID
- CHEMBL5095218
- InChIKey
- BHKKSKOHRFHHIN-MRVPVSSYSA-N
- PubChem compound IDs
- 121362450
- FDA ingredient codes (UNII)
- S6GYK3X4QQ
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- mitiperstat
- Type
- Synthetic organic
- Drug name stem
- -stat
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- myeloperoxidase
- Gene symbol
- MPO
- Protein identifier
- P05164
- Median affinity
- 9.15
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- thyroid peroxidase
- Gene symbol
- TPO
- Protein identifier
- P07202
- Median affinity
- 6.16
- Affinity units
- pIC50
- Action
- Irreversible inhibition
- Action type
- IRREVERSIBLE_INHIBITION
- Target
- myeloperoxidase
- Gene symbol
- MPO
- Protein identifier
- P05164
- Median affinity
- 8.82
- Affinity units
- pIC50
- Condition
- Cardiovascular Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000319
- Subject identifier
- D002318
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition
- Heart Failure
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003144
- Subject identifier
- D006333
- Condition identifier
- EFO_0000319
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003144
- Condition identifier
- EFO_0006890
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005002
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005252
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007027
- Highest recorded phase
- 2
- NCT02712372
- NCT03136991
- NCT04407091
- NCT03611153
- NCT03756285
- NCT04232345
- NCT04986202
- NCT04949438
- NCT05492877
- NCT05751759
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 3
- Polar surface area
- 79.6
- Calculated partition coefficient (ALogP)
- 3.11
- Calculated partition coefficient (XLogP)
- 1.7
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 22
- Molecular formula
- C15H15ClN4OS
- Monoisotopic mass
- 334.0655100
- Natural product
- No
- Recorded assays
- 46
- Active assays
- 13
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (14)
- A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease
- A Study in Participants With Non-cirrhotic NASH With Fibrosis
- A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers
- A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831
- A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers
- A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole
- A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.
- A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects
- An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.
- Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)
- Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment
- Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.
- Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of Midazolam
- Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
In development for (5)
- Cardiovascular disorder Phase 1
- Chronic obstructive pulmonary disease Phase 2
- Heart failure Phase 2
- Kidney disorder Phase 1
- Liver disorder Phase 1